The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 716.00
Bid: 716.50
Ask: 717.00
Change: 4.00 (0.56%)
Spread: 0.50 (0.07%)
Open: 716.00
High: 718.50
Low: 707.50
Prev. Close: 712.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Capital Markets Event

8 Feb 2023 07:00

RNS Number : 2128P
Tate & Lyle PLC
08 February 2023
 

8 February 2023 - Tate & Lyle PLC

 

Tate & Lyle Capital Markets Event

 

Tate & Lyle PLC (Tate & Lyle) is today hosting a Capital Markets event for investors and analysts.

 

The event will focus on the Group's strategy, business model, portfolio, markets, and science-led approach which puts it at the centre of the future of food. The event will be hosted by Nick Hampton, Chief Executive, Dawn Allen, Chief Financial Officer, alongside other members of the Tate & Lyle senior management team. 

 

Nick Hampton, Chief Executive said:

"Over the last five years, Tate & Lyle has been transformed into a growth-focused speciality food and beverage solutions business. A global leader in sweetening, mouthfeel and fortification, Tate & Lyle creates high-value speciality ingredients and solutions that meet growing global demand for healthier and tastier food and drink. 

 

At today's event we look forward to outlining the large and attractive markets we operate in, our portfolio of highly functional speciality ingredients that directly address growing consumer trends, our scientific and solutions capabilities, how we work with customers, and our purpose-driven approach fueling our new focus on 'Science, Solutions, Society'."

 

Performance ambition for the five years ending 31 March 2028

Today, Tate & Lyle is announcing an updated organic performance ambition for the five years ending 31 March 2028 to deliver:

• Revenue growth of 4% to 6% per annum, underpinned by high single digit Food & Beverage Solutions growth per annum

• EBITDA growth of 7% to 9% per annum

• Return on capital employed improvement of up to 50 basis points per annum on average.

• A new target to deliver US$100 million of cumulative productivity benefits

 

Reporting changes

Reflecting its new shape, the Group is adopting a simplified disclosure framework, moving to three segments - Food & Beverage Solutions, Sucralose and Primary Products Europe. As a result of this change, Central costs will no longer be reported separately.

 

Following the Group's recent third quarter trading update on 26 January 2023, no new material trading information or update in respect of the current financial year ending31 March 2023 will be provided during the event.

 

Registration is required to attend the event with details available on our website at https://www.tateandlyle.com/investors-hub. The slides to be presented at the event will be available from the investor relations section of our website shortly before the event, and the webcast of the presentation will be available shortly after the event. 

 

END

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle is a world leader in ingredient solutions for healthier food and beverages. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fortification, we develop solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.

We have more than 3,500 employees working in around 57 locations across 39 countries. Tate & Lyle's purpose is Transforming Lives Through the Science of Food and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2022, Tate & Lyle revenue from continuing operations totalled £1.4 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin, Facebook or YouTube

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBUGDDUUGDGXR
Date   Source Headline
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares
10th Aug 20222:15 pmRNSDirector/PDMR Shareholding
4th Aug 20223:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20224:00 pmRNSHolding(s) in Company
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.